Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Arnault, 2009, Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib, J Clin Oncol, 27, e59, 10.1200/JCO.2009.23.4823 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Hong, 2011, Overcoming metastatic melanoma with BRAF inhibitors, Arch Pharm Res, 34, 699, 10.1007/s12272-011-0521-5 Kong, 2008, Sorafenib-induced eruptive melanocytic lesions, Arch Dermatol, 144, 820, 10.1001/archderm.144.6.820 Tsoumpou, 2009, p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis, Cancer Treat Rev, 35, 210, 10.1016/j.ctrv.2008.10.005 Autier, 2008, Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor, Arch Dermatol, 144, 886, 10.1001/archderm.144.7.886 Szigeti, 2006, Autosomal-dominant calcium ATPase disorders, J Invest Dermatol, 126, 2370, 10.1038/sj.jid.5700447 Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 Su, 2012, RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors, N Engl J Med, 366, 207, 10.1056/NEJMoa1105358 Blank, 2012, Personal communication, ESMO Arnault, 2012, Skin tumors induced by sorafenib; paradoxic RAS–RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1, Clin Cancer Res, 18, 263, 10.1158/1078-0432.CCR-11-1344 Zimmer, 2012, Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition, J Clin Oncol, 30, 2375, 10.1200/JCO.2011.41.1660 Dalle, 2011, Vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 365, 1448, 10.1056/NEJMc1108651 Oberholzer, 2012, RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors, J Clin Oncol, 30, 316, 10.1200/JCO.2011.36.7680 Saltz, 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [abstract], J Clin Oncol, 22, 1201, 10.1200/JCO.2004.10.182 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Dummer, 2012, Ultraviolet A and photosensitivity during vemurafenib therapy, N Engl J Med, 366, 480, 10.1056/NEJMc1113752 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 Falchook, 2012, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial, Lancet Oncol, 13, 782, 10.1016/S1470-2045(12)70269-3